TY - JOUR T1 - Protocol for faecal microbiota transplantation in ulcerative colitis (FMTUC): a randomised feasibility study JF - BMJ Open JO - BMJ Open DO - 10.1136/bmjopen-2018-021987 VL - 8 IS - 10 SP - e021987 AU - Maki Jitsumura AU - Andrew Laurence Cunningham AU - Matthew David Hitchings AU - Saiful Islam AU - Angharad P Davies AU - Paula E Row AU - Andrew D Riddell AU - James Kinross AU - Tom S Wilkinson AU - G J Jenkins AU - John G Williams AU - Dean Anthony Harris Y1 - 2018/10/01 UR - http://bmjopen.bmj.com/content/8/10/e021987.abstract N2 - Background The interaction of the gut microbiota with the human host is implicated in the pathogenesis of inflammatory and immunological diseases including ulcerative colitis (UC). Faecal microbiota transplantation (FMT) as a method of restoring gut microbial diversity is of increasing interest as a therapeutic approach in the management of UC. The current literature lacks consensus about the dose of FMT, route of administration and duration of response.Methods and analysis This single-blinded randomised trial will explore the feasibility of FMT in 30 treatment-naïve patients with histologically confirmed distal UC limited to the recto-sigmoid region (up to 40 cm from the anal verge). This study aims to estimate the magnitude of treatment response to FMT under controlled conditions. The intervention (FMT) will be administered by rectal retention enema. It will test the feasibility of randomising patients to: (i) single FMT dose, (ii) five daily FMT doses or (iii) control (no FMT dose). All groups will receive standard antibiotic gut decontamination and bowel preparation before FMT. Recruitment will take place over a 24-month period with a 12-week patient follow-up. Trial objectives include evaluation of the magnitude of treatment response to FMT, investigation of the clinical value of metabolic phenotyping for predicting the clinical response to FMT and testing the recruitment rate of donors and patients for a study in FMT. This feasibility trial will enable an estimate of number of patients needed, help determine optimal study conditions and inform the choice of endpoints for a future definitive phase III study.Ethics and dissemination The trial is approved by the regional ethics committee and is sponsored by Abertawe Bro Morgannwg University’s Health Board. Written informed consent from all patients will be obtained. Serious adverse events will be reported to the sponsor. Trial results will be disseminated via peer review publication and shared with trial participants.Trial registration number ISRCTN58082603; Pre-results. ER -